<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Butalbital</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00241</strong>&#160; (APRD00266)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit</td></tr><tr><th>Description</th><td><p>Butalbital, 5-allyl-5-isobutylbarbituric acid, is a barbiturate with an intermediate duration of action. It has the same chemical formula as talbutal but a different structure. Butalbital is often combined with other medications, such as acetaminophen or aspirin, and is commonly prescribed for the treatment of pain and headache. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00241/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00241/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00241.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00241.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00241.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00241.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00241.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00241">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>5-isobutyl-5-allylbarbituric acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>allylbarbital</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>allylbarbitone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Sandoptal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Alagesic</td><td>Caffeine + Butalbital + Acetaminophen</td></tr><tr><td>BUPAP</td><td>Butalbital + Acetaminophen</td></tr><tr><td>Butapap</td><td>Butalbital + Acetaminophen</td></tr><tr><td>Capacet</td><td>Caffeine + Butalbital + Acetaminophen</td></tr><tr><td>Esgic-Plus</td><td>Caffeine + Butalbital + Acetaminophen</td></tr><tr><td>Fiorinal C1/2 Cap</td><td>Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate</td></tr><tr><td>Fiorinal C1/4 Cap</td><td>Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate</td></tr><tr><td>Fiorinal Tab</td><td>Acetylsalicylic Acid + Butalbital + Caffeine</td></tr><tr><td>ORBIVAN</td><td>Caffeine + Butalbital + Acetaminophen</td></tr><tr><td>Phrenilin</td><td>Butalbital + Acetaminophen</td></tr><tr><td>Ratio-Tecnal</td><td>Acetylsalicylic Acid + Butalbital + Caffeine</td></tr><tr><td>Ratio-Tecnal C 1/2</td><td>Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate</td></tr><tr><td>Ratio-Tecnal C1/4</td><td>Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate</td></tr><tr><td>Trianal Capsules</td><td>Acetylsalicylic Acid + Butalbital + Caffeine</td></tr><tr><td>Trianal Tablet</td><td>Acetylsalicylic Acid + Butalbital + Caffeine</td></tr><tr><td>Trianal-C 1/2 Capsule</td><td>Acetylsalicylic Acid + Butalbital + Caffeine + Codeine Phosphate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>77-26-9</td></tr><tr><th>Weight</th><td>Average: 224.2563<br>Monoisotopic: 224.116092388</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>UZVHFVZFNXBMQJ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-(2-methylpropyl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Barbituric Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Ureides; Diazinanes; N-unsubstituted Carboxylic Acid Imides; Secondary Carboxylic Acid Amides; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>ureide; 1,3-diazinane; carboxylic acid imide, n-unsubstituted; carboxamide group; secondary carboxylic acid amide; carboxylic acid derivative; polyamine; carboxylic acid; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain.</td></tr><tr><th>Pharmacodynamics</th><td>Butalbital is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.</td></tr><tr><th>Mechanism of action</th><td>Butalbital binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.</td></tr><tr><th>Absorption</th><td>Well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>45%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, although most of the dose is eliminated via the kidney (59 to 88%). Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8%).</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>35 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension, and shock.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9112</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9703</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5936</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5365</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5179</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9678</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9331</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7999</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8708</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6804</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8535</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8768</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9324</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8354</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9074</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9626</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5716
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8861
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9833
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0783 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9898
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9711
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.atley.com">Atley Pharmaceuticals</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.chattem.com">Chattem Chemicals Inc.</a></li>
<li>D.M. Graham Laboratories Inc.</li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.ecrpharma.com">ECR Pharmaceuticals</a></li>
<li><a href="http://www.everettlabs.com">Everett Laboratories Inc.</a></li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li><a href="http://www.intetlab.com">International Ethical Labs Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Marnel Pharmaceuticals Inc.</li>
<li><a href="http://www.mcramerican.com">MCR American Pharmaceuticals Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.merz.com">Merz Pharmaceuticals LLC</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.savagelabs.com">Savage Labs</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li>Va Cmop Dallas</li>
<li><a href="http://www.valeant.com">Valeant Ltd.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. </td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>The barbiturate, butalbital, decreases the effect of aminophylline.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone.</td></tr><tr><td><a href="/drugs/DB00446">Chloramphenicol</a></td><td>Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB00882">Clomifene</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00286">Conjugated Estrogens</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, conjugated estrogens.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The barbiturate, butalbital, increases the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone.</td></tr><tr><td><a href="/drugs/DB00255">Diethylstilbestrol</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, diethylstilbestrol.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>The anticonvulsant, butalbital, decreases the effect of doxycycline.</td></tr><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>Droperidol may enhance the CNS depressant effect of CNS depressants such as butalbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.
</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag.</td></tr><tr><td><a href="/drugs/DB00783">Estradiol</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, estradiol.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB01023">Felodipine</a></td><td>The barbiturate, butalbital, decreases the effect of felodipine.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone.</td></tr><tr><td><a href="/drugs/DB00158">Folic Acid</a></td><td>Folic acid decreases the effect of anticonvulsant, butalbital.</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>The barbiturate, butalbital, decreases the effect of griseofulvin.</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone.</td></tr><tr><td><a href="/drugs/DB00557">Hydroxyzine</a></td><td>Hydroxyzine may enhance the CNS depressant effect of barbiturates such as butalbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination. </td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB00367">Levonorgestrel</a></td><td>Phenobarbital decreases the effect of levonorgestrel</td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone.</td></tr><tr><td><a href="/drugs/DB00351">Megestrol acetate</a></td><td>The enzyme inducer, butalbital, decreases the effect of the hormone agent, megestrol.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The barbiturate, butalbital, decreases the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00916">Metronidazole</a></td><td>The barbiturate, butalbital, decreases the effect of metronidazole.</td></tr><tr><td><a href="/drugs/DB01115">Nifedipine</a></td><td>The barbiturate, butalbital, decreases the effect of the calcium channel blocker, nifedipine.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>This product may cause a slight decrease of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>The barbiturate, butalbital, decreases the effect of oxtriphylline.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. </td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>The anticonvulsant, butalbital, decreases the effect of quinidine.</td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>Barbiturates such as butalbital may decrease the serum concentration of teniposide. Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely. </td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>The barbiturate, butalbital, decreases the effect of theophylline.</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The barbiturate, Butalbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butalbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Butalbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>